Vitamin

Vitamin E

α-Tocopherol (RRR-α-tocopherol)

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

15 mg (RDA), 400-800 IU (NASH therapy)

watchEffect Window

3-6 months for liver histology improvements.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Vitamin E includes tocopherols and tocotrienols that protect cell membranes from oxidative damage. It is used to correct deficiency in fat malabsorption and to modulate oxidative stress biomarkers.

Vitamin E correction improves neurologic and immune function in malabsorption-related deficiency by protecting membrane lipids. Recent umbrella-review evidence supports modest improvements in nonalcoholic fatty liver disease liver enzymes, steatosis, and some fibrosis measures, but this remains a disease-specific use case rather than a general antioxidant license. Minority studies examine cognitive decline and cardiovascular prevention with mixed or negative results. High-dose intake can increase bleeding risk, especially with anticoagulants, which can reduce net benefit.

Primary fat-soluble antioxidant residing in cell membranes. Neutralizes lipid peroxyl radicals and inhibits platelet aggregation.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • First-line NASH therapy at 800 IU/day (PIVENS trial)

Secondary Outcomes

  • Cell membrane antioxidant protection
  • Immune modulation in elderly

Safety

Contraindications and Interactions

Contraindications

  • Vitamin K deficiency
  • Active bleeding
  • Pre-surgical (stop 2 weeks before)

Side effects

  • Nausea
  • Fatigue
  • Headache at high doses
  • Easy bruising
  • Increased bleeding risk

Interactions

  • Warfarin/anticoagulants (increased bleeding)
  • Statins+niacin (may reduce HDL benefit)
  • Chemotherapy (antioxidant interference)

Avoid if

  • Elevated prostate cancer risk
  • Anticoagulant therapy
  • Vitamin K deficiency

Evidence

Study-level References

vitamin-e-SRC-001Randomized controlled trial (PIVENS)
Sourceopen_in_new

Sanyal AJ, Chalasani N, Kowdley KV, et al. "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis." N Engl J Med. 2010.

Population: Non-diabetic adults with biopsy-confirmed NASH

Key findings: Vitamin E 800 IU/day significantly improved NASH histology compared to placebo, establishing it as first-line therapy for non-diabetic NASH.

Paper content

Vitamin E 800 IU/day significantly improved NASH histology compared to placebo, establishing it as first-line therapy for non-diabetic NASH.

vitamin-e-SRC-001AUmbrella review of meta-analyses on randomized controlled trials
Sourceopen_in_new

Wang MY, et al. Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials. J Dig Dis. 2023;24(6-7):380-389. doi:10.1111/1751-2980.13210. PMID:37503812.

Population: Patients with nonalcoholic fatty liver disease across meta-analyses of randomized trials.

Dose protocol: Vitamin E protocols pooled across NAFLD randomized-trial meta-analyses, with stronger fibrosis signals at doses above 600 IU/day and durations of at least 12 months

Key findings: Umbrella-review evidence found improvements in ALT, AST, steatosis, and fibrosis signals in NAFLD, strengthening the modern liver-specific case for vitamin E while keeping it disease-bound.

Notes: Helpful modernization source because it broadens the liver evidence beyond the original PIVENS trial without changing the safety concerns around chronic high-dose use.

Paper content

This umbrella review found that vitamin E supplementation improved ALT, AST, fibrosis, and steatosis outcomes in NAFLD. The fibrosis signal was strongest when vitamin E doses exceeded 600 IU daily or treatment lasted at least 12 months.

vitamin-e-SRC-002Meta-analysis of randomized controlled trials
Sourceopen_in_new

Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality." Ann Intern Med. 2005.

Population: Adults in vitamin E supplementation trials

Key findings: High-dose vitamin E (≥400 IU/day) was associated with a small but significant increase in all-cause mortality.

Paper content

High-dose vitamin E (≥400 IU/day) was associated with a small but significant increase in all-cause mortality.

vitamin-e-SRC-003Randomized controlled trial
Sourceopen_in_new

Klein EA, Thompson IM Jr, Tangen CM, et al. "Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)." JAMA. 2011.

Population: Healthy men ≥50 years

Key findings: Vitamin E 400 IU/day increased prostate cancer risk by 17% compared to placebo over extended follow-up.

Paper content

Vitamin E 400 IU/day increased prostate cancer risk by 17% compared to placebo over extended follow-up.

vitamin-e-SRC-004Systematic review.
Sourceopen_in_new

Amin AM, Mostafa H, et al. Vitamin E and cognitive function: a systematic review of clinical evidence. Nutr Res. 2026. doi:10.1016/j.nutres.2025.11.009. PMID:41418497.

Population: Over 80,000 participants across 43 clinical studies published between 2012 and 2022.

Dose protocol: Systematic review of 43 clinical studies with 80,000+ participants examining vitamin E and cognitive function (2012 to 2022)

Key findings: Dietary vitamin E and multivitamin formulations showed protective association with cognitive function. Evidence for isolated vitamin E supplementation alone was less consistent.

Notes: Supports the food-matrix and combination-supplement context over high-dose isolated supplementation for cognitive outcomes.

Paper content

This systematic review analyzed 43 clinical studies with over 80,000 participants to evaluate the relationship between vitamin E and cognitive function. The review found that vitamin E consumed as a dietary component or as part of multivitamin supplements containing other vitamins, herbs, and minerals was associated with a protective effect against cognitive decline. However, evidence for vitamin E supplements taken alone was less consistent. Research on tocotrienols and other vitamin E isoforms remains limited. This aligns with the broader vitamin E narrative where dietary adequacy and food-matrix effects may matter more than isolated high-dose supplementation.

Guides

Setup

Help